A double-blind, randomized controlled clinical trial conducted by Stanford University researchers has demonstrated that pulsed shortwave therapy provides sustained pain relief for adults with thumb carpometacarpal joint osteoarthritis, one of the most common and painful forms of hand arthritis. The study, published in the Journal of Hand Surgery, offers promising evidence for a non-pharmaceutical treatment option that patients can self-administer at home.
Thumb arthritis affects an estimated 4-7 million U.S. adults, making everyday tasks like turning doorknobs, buttoning shirts, or opening jars difficult and painful. Current treatment options are limited, typically involving splints, medications, or injections, which often provide temporary relief or come with side effects. The Stanford study suggests PSWT could represent a significant advancement in managing this widespread condition.
The research involved 61 adults with clinically and/or radiographically diagnosed thumb CMC osteoarthritis who were randomly assigned to use either an active PSWT device or an identical-appearing sham device. Both groups wore their devices for approximately eight hours each night over a four-week period. The study abstract can be viewed at https://journals.sagepub.com/doi/10.1177/15589447251371088.
At the four-week mark, both groups reported meaningful reductions in pain, likely influenced by the splint-like stiffness of the devices and potential placebo effects. However, the critical finding emerged after device use was discontinued. By week six, only the PSWT group maintained its pain relief, while the sham group did not. The difference in pain reduction between PSWT and sham groups at this point was highly statistically significant with a p value of .02.
Other measures including maximum pain, hand function as measured by the Patient-Rated Wrist Hand Evaluation, and single-assessment numeric evaluation scores improved in both groups during the treatment period. Importantly, PSWT was found to be safe and well tolerated throughout the study. Adverse events were infrequent and mild, most commonly minor skin irritation from the adhesive tape, with no serious adverse events reported.
The sustained benefit observed in the PSWT group suggests the therapy offers genuine analgesic effects beyond mere splinting or placebo responses. This distinction is crucial because it indicates PSWT may provide lasting relief even after treatment cessation, unlike many current interventions that require ongoing use. The technology represents a shift toward non-invasive, drug-free pain management options that patients can incorporate into their daily routines without systemic side effects.
BioElectronics Corporation, the developer of PSWT technology, markets the ActiPatch device as an over-the-counter treatment option. More information about the company and its products is available at https://www.bielcorp.com/. The affordability and accessibility of such devices could potentially transform pain management for millions suffering from thumb arthritis, reducing reliance on medications and invasive procedures while improving quality of life and functional capacity.
